Requests · The University of Texas Health Science Center at San Antonio
T3: Translational Therapeutics for Texas
Priority 2 · one of 3 items in the The University of Texas Health Science Center at San Antonio's request for 2028-29 · The item begins on page 109 of the request
This is a request, not an appropriation.
What is asked
| 2028 | 2029 | Two years | |
|---|---|---|---|
| All funds | $12,500,000 | $12,500,000 | $25,000,000 |
| Of which general revenue and general revenue-dedicated | $12,500,000 | $12,500,000 | $25,000,000 |
| Positions (full-time equivalents) | 12.0 | 15.0 |
How it would be financed
| Method of financing, as the request prints it | 2028 | 2029 |
|---|---|---|
| 1 General Revenue Fund | $12,500,000 | $12,500,000 |
| Total, as the request prints it | $12,500,000 | $12,500,000 |
Where it would land
The strategies this item would add to, numbered as the request numbers them, beside what each is appropriated in the current budget (2026-27 Act). One column is an appropriation and the other a request made on top of a base request not shown here, so the two are not subtracted.
| Strategy | Asked 2028 | Asked 2029 | Positions | Appropriated 2026 | Appropriated 2027 |
|---|---|---|---|---|---|
| 05-04-01 Exceptional Item Request | $12,500,000 | $12,500,000 | 15.0 | No strategy matched in the current budget | |
A strategy is matched by its name. Where none is matched, the strategy may be new, or may be in the current budget under a different name.
After 2029
| The agency's estimate | 2030 | 2031 | 2032 | Three years |
|---|---|---|---|---|
| All funds | $12,500,000 | $12,500,000 | $12,500,000 | $37,500,000 |
| Of which general revenue | $12,500,000 | $12,500,000 | $12,500,000 | $37,500,000 |
In the agency's words: FY2028-32 costs are recurring: regulatory/IND, shared-facility and staff, faculty recruitments/retention. Instrument acquisition planned in FY2028-29; instrumentation costs shift in FY2030 to service contracts, maintenance, and phased replacement.
The agency's justification
UT Health Science Center San Antonio is uniquely poised to deliver a groundbreaking drug-development initiative, Translational Therapeutics for Texas (T3), designed to turn university discoveries into investigational new drugs (INDs) -- the treatments cleared to enter human clinical trials -- for Texas patients. T3 targets diseases that burden Texans: cancer, including childhood and pancreatic cancers; Alzheimer's disease; and disorders of pain, addiction, and mental health. Building on the Health Science Center's NCI-designated cancer center, a CPRIT- and NCI-supported drug-discovery center (CIDD), and strong pharmacology and structural biology programs, T3 will move new medicines from laboratory discovery toward the clinic. This directly advances the national Genesis Mission and its NIH-led Bio Genesis Mission (July 2026), which commit federal funding to speed drug discovery and aim to halve the time it takes for discoveries to reach patients, positioning Texas to compete for that investment. Beyond improving lives, T3 keeps the resulting intellectual property, companies, jobs, and clinical activity in Texas, strengthening the state's economy and life-sciences industry. This request supports four senior scientist faculty recruits across the Departments of Pharmacology and Biochemistry and Structural Biology, support staff, a regulatory team that prepares medicines for FDA review, and shared instrumentation for structural biology, mass spectrometry, and pharmacology.
External and internal factors
Internally, the September 2025 merger that brought together UT Health Science Center San Antonio and UT San Antonio placed under one institution a unique array of capabilities bringing together most elements of a drug-development pipeline. The translational instrumentation and faculty this request provides are the principal remaining gap. The institution is planning to invest $65 million through its Nexus Initiative in multi- omics and AI-informed high-performance computing; because those investments cannot pay for faculty or operations, this request funds what they cannot. T3 is deliberately complementary to existing Texas capability, which is concentrated in oncology. It extends drug development into broader diseases impacting Texans, drawing on one of the nation's largest early-phase trial programs. San Antonio adds a partner ecosystem no other Texas metro matches: Southwest Research Institute, Texas Biomedical Research Institute, UT San Antonio, the 900-acre South Texas Medical Center, and a large military medical community. Institutional master planning includes a Discovery Park to host industry partners and start-ups. Externally, drug discovery is a declared national priority: the July 2026 Genesis and Bio Genesis Missions direct billions toward AI-enabled discovery. Competition for scientists is intense.
As marked in the request
- Has an information technology part: No
- Costs anticipated after the two budget years: Yes
- Involves contracts over $50,000: Yes